Plain-English translation of NCT06249750 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing a new combination approach for metastatic castration-resistant prostate cancer (advanced prostate cancer that has stopped responding to hormone treatment). Half of the participants will receive two drugs called Tislelizumab and Anlotinib. The other half will receive the same medications plus whole-body near-infrared heat treatment, where your body temperature is carefully raised to about 101–102°F and held there for one hour. Researchers believe adding heat therapy may help the work better.
Advanced prostate cancer that stops responding to hormone therapy is very difficult to treat, and current options have limited success. This study explores whether combining heat with could improve how well the medication works and help patients live longer with better quality of life.
You likely qualify if…
You likely don't qualify if…
You will be randomly assigned to one of two groups. Both groups take two medications by mouth and injection every three weeks for an extended period. If you're in the heat-plus- group, you'll also receive whole-body heat treatment twice per cycle, where special infrared equipment gradually raises your core body temperature to about 101–102°F for one hour. You'll have regular clinic visits for blood tests, check-ups, and monitoring. The study includes long-term follow-up to track how you're doing and how the treatment affects your quality of life.
AI-generated summary from trial data · Jun 18, 2026 · Not medical advice
China